Angiotensinogen, Angiotensin-Converting Enzyme, and Chymase Gene Polymorphisms as Biomarkers for Basal Cell Carcinoma Susceptibility

Christos Yapijakis; Iphigenia Gintoni; Sevastiana Charalampidou; Antonia Angelopoulou; Veronica Papakosta; Stavros Vassiliou; George Chrousos

doi:10.1007/978-3-031-31978-5_14

Back

Angiotensinogen, Angiotensin-Converting Enzyme, and Chymase Gene Polymorphisms as Biomarkers for Basal Cell Carcinoma Susceptibility

Article 2023 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2016

Inhibiting angiotensin-converting enzyme promotes renal repair by modulating progenitor cell activation

Paola Rizzo, Rubina Novelli, Ariela Benigni, Giuseppe Remuzzi

Article2024

Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease

Elaine Ku, Lesley A. Inker, Hocine Tighiouart, Charles E. McCulloch, Ogechi M. Adingwupu, Tom Greene, Raymond O. Estacio, Mark Woodward, Dick de Zeeuw, Julia B. Lewis, Thierry Hannedouche, Tazeen H. Jafar, Enyu Imai, Giuseppe Remuzzi, Hiddo J.L. Heerspink, Fan Fan Hou, Robert D. Toto, Philip Kam‐Tao Li, Mark J. Sarnak

Letter2005

The angiotensin‐converting enzyme gene insertion/deletion polymorphism: insufficient evidence for a role in deep venous thrombosis

Emilie P. Buddingh, Astrid van Hylckama Vlieg, Frits R. Rosendaal

Journal of Thrombosis and Haemostasis

Article2005

Angiotensin-Converting Enzyme Inhibition and Renal Protection in Nondiabetic Patients

Carlos Chiurchiu, Giuseppe Remuzzi, Piero Ruggenenti

Article1997

Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease

Piero Ruggenenti, Giuseppe Remuzzi